Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction
Information source: Merck KGaA
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Ovulation Induction
Intervention: Recombinant FSH (follitropin alpha) (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Merck KGaA Official(s) and/or principal investigator(s): Khaled Esmat, MD, Study Director, Affiliation: Merck Serono Middle East FZ-LLC, United Arab Emirates, an affiliate of Merck KGaA, Darmstadt, Germany
Summary
This is an open-label, prospective, randomized, controlled, multicentric, multinational,
phase IV study to evaluate the use of Gonal-f in inducing ovulation in female subjects with
chronic anovulation. It has been observed that conventional high dose set up regimen of
gonadotropin and human chorionic gonadotropin (hCG) is effective in anovulatory subjects in
terms of overall pregnancy rates. However, development of multiple follicles leading to
multiple pregnancy and/or ovarian hyperstimulation syndrome (OHSS) is the major
complications associated with this high dose set up. Chronic low-dose (CLD) protocols of
follicle stimulating hormone (FSH), aimed at finding the threshold amount of FSH necessary
to promote monofolliculogenesis, have been found to be successful in reducing the rate of
OHSS almost to nil and the rate of multiple pregnancies to a minimum. This post-marketing
study will investigate tailoring of recombinant follicle stimulating hormone (r-FSH) in a
large population (N=310) of subjects from a region (North Africa/Middle East) that has not
been included in previous studies of ovulation induction in subjects with chronic
anovulation. The study aims to increase current knowledge of the efficacy and safety of
Gonal-f, and provide fertility physicians with experience in Gonal-f treatment in
anovulatory infertility, thereby contributing to the development of FSH dosing guidelines
for ovulation induction by defining the optimal CLD and Low dose (LD) regimens.
Clinical Details
Official title: A Phase IV, Open-label, Post Marketing, Prospective, Randomized, Controlled, Multicentre, Multinational Study to Investigate Tailoring of Recombinant FSH Use in Ovulation Stimulation Treatment in Chronic Anovulatory Subjects (WHO Group II)
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Percentage of Participants With a Mono-follicular Development
Secondary outcome: Number of Participants With Multi-follicular DevelopmentNumber of Participants With Adverse Events (AEs) Number of Participants With Multiple Pregnancies Number of Participants With Injection Tolerability Number of Participants Who Received Human Chorionic Gonadotropin (hCG) Number of Participants With Cancelled Cycles Number of Participants With Clinical Pregnancies Duration of Follicle Stimulating Hormone (FSH) Total Follicle Stimulating Hormone (FSH) Dose Number of Participants Who Answered Ease of Use of Gonal-f® Pen Questionnaire
Detailed description:
Gonal-f is a recombinant form of human FSH (r-hFSH), an endogenous gonadotropin which is
being produced in genetically engineered chinese hamster ovary cells and is indicated for
induction of ovulation and pregnancy in anovulatory infertile women in whom the cause of
infertility is functional and not due to primary ovarian failure. It is also indicated for
the development of multiple follicles in ovulatory women participating in an assisted
reproductive technology (ART) programme, such as in in vitro fertilization (IVF). The
primary cause of infertility in women is an abnormality of ovulation. Most of these
anovulatory subjects fall into the World Health Organization (WHO) Group II category,
characterized by asynchronous gonadotropin and oestrogen production and normal levels of
prolactin (PRL). These subjects present with a variety of menstrual disorders, most commonly
polycystic ovarian syndrome (PCOS).
Gonal-f is administered as a course of daily injections, subcutaneously into the anterior
abdominal wall. A commonly used regimen commences at 75-150 IU FSH daily and is increased
preferably by 37. 5 IU, or 75 IU at 7 or preferably 14 day intervals if necessary, to obtain
an adequate but not excessive response. A single injection of 5,000 IU urinary hCG (u-hCG)
(or 250 microgram [mcg] r-hCG) should be administered after the last dose of Gonal-f and
when the leading follicle has reached 17 mm in diameter. The subject is later recommended to
have coitus on the day of, and the day following, hCG administration. The efficacy of
Gonal-f in the treatment of WHO Group II anovulatory infertile women has been confirmed by 2
randomized, open-label, multicentric, phase III non-inferiority studies that compared
Gonal-f with Metrodin® (urinary FSH) for ovulation induction. The possible serious adverse
events (SAEs) associated with Gonal-f include OHSS and its possible complications, multiple
pregnancies, pregnancy wastage, ectopic pregnancies and the possible risk of ovarian cancer
and reproductive system neoplasms (e. g. endometrial, breast carcinoma).
OBJECTIVES
Primary objective:
- To investigate tailoring of recombinant FSH treatment in subjects with chronic
anovulation
Secondary objectives:
- To evaluate commonly used ovulation induction regimens and treatments
- To establish local experience with the Gonal-f pen and investigate ease of use
The study will enroll 310 eligible subjects, randomized in a 1: 1 ratio to either Group I or
II at the baseline visit prior to the first dose of FSH (pre-stimulation). Each subject will
be refrained from the use of gonadotropins or any other ovulation stimulation therapy during
the period from screening to the start of stimulation treatment. During the stimulation
period, Gonal-f will be administered as a course of once daily (OD) injections, s. c. into
the anterior abdominal wall through Gonal-f pen, according to either one of the following 2
step-up, low-dose regimens:
Group I: CLD regimen which recommends a starting dose of 75 IU and a first adjustment on Day
14 of stimulation, if no ovarian response is observed.
Group II: LD regimen which recommends a starting dose of 75 IU and a first adjustment on Day
7 of stimulation, if no ovarian response is observed.
For both groups, when at least 1 follicle reaches 10 to 12 mm in diameter, the Gonal-f
administration will be maintained at that dose until the leading follicle reaches 17 mm or
more in diameter and no more than 2 follicles have reached 14 mm in diameter. A single
injection of hCG (5,000 IU u-hCG or 250 mcg r-hCG) will be administered intramuscularly or
subcutaneously after the last Gonal-f injection, to trigger ovulation. Subjects will also be
advised to have coitus on the day of, and the day following hCG administration. The total
length of the stimulation treatment will not exceed 35 days unless an ultrasound assessment
suggests imminent follicular growth and maturation and each subject will undergo one cycle
of stimulation treatment only. Subjects will also be followed for a post stimulation period
of up to 20 days after the triggering of ovulation by hCG injection, or cancellation of the
cycle.
Eligibility
Minimum age: 18 Years.
Maximum age: 37 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Premenopausal female subjects, aged between 18 and 37 years inclusive
- Subjects willing to conceive
- Subjects who are infertile due to chronic anovulation demonstrated by a cycle
duration of > 35 days, or regular cycles with progesterone (P4) levels < 1
nanomole/milliliter (nmol/mL) during luteal phase (Day 25)
- Subjects who have experienced spontaneous menses, menses induced by clomiphene
citrate therapy, or a positive progestin-induced withdrawal within the previous year
- Subjects with FSH and PRL serum values within the normal range in the early
follicular phase
- Subjects with total antral follicle count (AFC) > 10 (of follicle size ≥ 2 mm and <
11 mm) in both ovaries
- Subjects with at least 1 patent tube, as documented by recent (within 2 years before
treatment assignment) hysterosalpingography (HSG)
- Subjects with normal uterine cavity, as documented by recent (within 2 years before
treatment assignment) hysteroscopy, HSG or ultrasound scan
- Subjects with body mass index (BMI) >20 and ≤32 kilogram square per meter (kg/m^2)
- Subjects with negative cervical Papanicolaou (PAP) test within the 6 months prior to
screening
- Male partners of female subjects with sperm compatible with non assisted
fertilization
- Subjects who are willing and able to participate in the study and have provided
written, informed consent
Exclusion Criteria:
- Subjects with history of hypersensitivity to the active substance follitropin alpha,
FSH, or to any of the excipients of Gonal-f
- Subjects with ovarian enlargement or ovarian cyst unrelated to PCOS, and of unknown
origin on ultrasound
- Subjects with evidence of diminished ovarian reserve (cycle length < 26 days; FSH
above the upper limit of local serum FSH values, total AFC in both ovaries < 10)
- Subjects with myomatous uterus, which in the opinion of the investigator could impair
pregnancy evolution
- Subjects who have undergone 3 or more previous miscarriages
- Subjects with any previous extrauterine pregnancy
- Pregnant or lactating female subjects
- Subjects with abnormal gynecological bleeding of unknown etiology
- Subjects with previous history of severe OHSS
- Subjects who have undergone operative pelvic surgery which could induce mechanical
infertility (e. g tubes blockage) or pelvic inflammatory disease (PID) before
treatment assignment excluding curettage and hysteroscopy
- Subjects with tumors of the hypothalamus and pituitary gland
- Subjects with ovarian, uterine or mammary carcinoma
- Subjects treated with clomiphene citrate or gonadotropins within 1 month of the
screening evaluation
- Subjects with any medical condition which, in the opinion of the investigator, would
prevent an effective response, such as primary ovarian failure, or malformations of
the reproductive organs incompatible with pregnancy
- Subjects with any medical condition which, in the opinion of the investigator, may
interfere with the absorption, distribution, metabolism or excretion of the drug
- Subjects with any clinically significant systemic disease (e. g. insulin-dependent
diabetes) or any contraindication to being pregnant and/or carrying a pregnancy to
term; also including subjects with non insulin dependent diabetes mellitus (NIDDM)
- An active substance abuser
- Subjects with known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or
C virus in the trial subject or her male partner
- Subjects who have simultaneously participated in another clinical trial
Locations and Contacts
Mount Lebanon Hospital, Hazmieh, P.O.Box 470, Lebanon
New Mowasat Hospital, Salmiya, P.O.Box 6661 22077, Kuwait
King Abdel Aziz University Hospital, Jeddah, P.O.Box 80215 21589, Saudi Arabia
Additional Information
Starting date: March 2009
Last updated: January 20, 2014
|